Consensus Tharimmune, Inc.

Equities

THAR

US4327052001

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.361 ^USD	-1.98%		-4.01%	-29.08%

May. 09	Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	CI

Evolution of the average Target Price on Tharimmune, Inc.

Price target over the last 5 years

History of analyst recommendation changes

39f6ca890c42354c9fcb6925bb49a8.3fO71evDMMU-fe538l2RVuzDaR3SJurRfnI7548XHzw.tL2JoY6MY6tWMpc6yzfgY6iXNlbrFd-GOzgNhMxjV1q3gNCEu61mswgw1g~866dc911e87eea5d769fc24a40f1564a

Analyst Recommendations on Tharimmune, Inc.

Dawson James Downgrades Hillstream BioPharma to Neutral From Buy

23-07-17

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.361 USD

Average target price

5 USD

Spread / Average Target

+1,285.04%

High Price Target

5 USD

Spread / Highest target

+1,285.04%

Low Price Target

5 USD

Spread / Lowest Target

+1,285.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tharimmune, Inc.

Dawson James

Annual profits - Rate of surprise

Company calendar